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Viral persistence specifically inhibits CD4 Th1 re-
sponses and promotes Tfh immunity, but the mech-
anisms that suppress Th1 cells and the disease
consequences of their loss are unclear. Here, we
demonstrate that the loss of CD4 Th1 cells specif-
ically leads to progressive CD8 T cell decline and
dysfunction during viral persistence. Therapeutically
reconstituting CD4 Th1 cells restored CD4 T cell
polyfunctionality, enhanced antiviral CD8 T cell
numbers and function, and enabled viral control.
Mechanistically, combined interaction of PD-L1 and
IL-10 by suppressive dendritic cell subsets inhibited
new CD4 Th1 cells in both acute and persistent virus
infection, demonstrating an unrecognized suppres-
sive function for PD-L1 in virus infection. Thus, the
loss of CD4 Th1 cells is a key event leading to
progressive CD8 T cell demise during viral persis-
tence with important implications for restoring anti-
viral CD8 T cell immunity to control persistent viral
infection.
INTRODUCTION
In response to many persistent virus infections, virus-specific
T cells are either physically deleted or persist in an attenuated
(exhausted) state characterized by a distinct transcriptional pro-
gram, alterations in antiviral and immune-stimulatory cytokines,
and a decreased ability to proliferate or lyse virally infected cells
(Ng et al., 2013;Wherry and Kurachi, 2015). Although CD4 T cells
are the central orchestrators of the immune response, to date the
majority of work analyzing T cell dynamics and exhaustion during
persistent viral infection has focused on CD8 T cells. In fact,
effectively directed and sustained CD4 T cell responses are the
best correlates of control and clearance of multiple persistent3286 Cell Reports 16, 3286–3296, September 20, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://virus infections (Ng et al., 2013). Thus, understanding how CD4
T cells mediate control of persistent infection will be critical for
designing therapies to fight viral infections.
Upon activation, naive CD4 T cells differentiate into specific
subsets (Th1, Tfh, Th17, T regulatory cell [Treg], etc.) based on
signals from the antigenic environment and interactions with an-
tigen-presenting cells (APCs) (Zhu et al., 2010). The CD4 T helper
(Th) response generated is tailored to control individual types of
pathogens, with misdirection often leading to ineffective immu-
nity (Hegazy et al., 2010; MacDonald et al., 2002). In response
to viral infections, CD4 T cells predominantly differentiate into
Th1 cells that sustain CD8 T cell responses to kill virus-infected
cells (Battegay et al., 1994; Elsaesser et al., 2009; Fro¨hlich et al.,
2009; Matloubian et al., 1994; Yi et al., 2009) or develop into T
follicular helper (Tfh) cells that mediate B cell differentiation
and antibody production (Crotty, 2014; Fahey et al., 2011).
Although CD4 help at the onset of persistent virus infection is
initially required to promote the CD8 T cell and antibody re-
sponses required for long-term control of infection (Bergthaler
et al., 2009; Fahey et al., 2011), the subsets best suited to main-
tain long-term immunity and control an established persistent
virus infection are unclear.
During viral persistence, continuous T cell receptor (TCR) stim-
ulation progressively drives transformation of virus-specific CD4
Th1 cells into Tfh cells (Fahey et al., 2011), and, ultimately, the
CD4 Th1 cells generated at the onset of persistent infection
are lost, leaving primarily B cell-helping CD4 Tfh cells. Furthering
the skew toward Tfh, we recently identified a severe defect in the
ability to generate new virus-specific CD4 Th1 cells in the midst
of an established persistent virus infection (Osokine et al., 2014).
In the established persistent virus infection, only new CD4 Tfh
cells were generated (Osokine et al., 2014), leaving a hole in
the CD4 Th subset repertoire and skewing the type of help avail-
able as persistent infection progressed.
A similar decrease in CD4 Th1 cells and accumulation of Tfh
cells is observed in HIV, simian immunodeficiency virus (SIV),
and hepatitis C virus (HCV) infections (Feng et al., 2012; Lindqvist
et al., 2012; Petrovas et al., 2012), suggesting a conserved lossuthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
Cell Reports 16, 3286–3296, September 20, 2016 3287
of Th1 responses in persistent virus infection. Interestingly, pro-
longed CD4 Th1 responses in HIV and HCV infections correlate
with enhanced viral control (Gerlach et al., 1999; Rosenberg
et al., 1997; Thimme et al., 2001). However, it remains unclear
whether sustained Th1 responses actually facilitate viral control
or whether decreased viral loads simply enable Th1 priming and
maintenance. Differentiating between these scenarios will be
critical to determine the role of Th1 cells in persistent infection
and further the understanding of which CD4 T cell subsets are
optimal to therapeutically decrease viral replication.
Here we demonstrate the fundamental disease consequences
of the loss and inability to generate new CD4 Th1 cells during
viral persistence. We demonstrate that the loss of CD4 Th1 cells
underlies the progressive CD8 T cell decline and dysfunction that
prevents control of persistent infection and that therapeutically
restoring CD4 Th1 cells enhances virus-specific CD8 T cell
numbers and function, facilitating control of the persistent infec-
tion. Mechanistically, expression of PD-L1 and interleukin-10
(IL-10), two immunosuppressive molecules integrally linked to
the failure to control persistent virus infections (Barber et al.,
2006; Brooks et al., 2006; Day et al., 2006; Ejrnaes et al.,
2006), by suppressive dendritic cells (DCs) simultaneously in-
hibits CD4 Th1 immunity. Further, these same mechanisms
also impede CD4 Th1 differentiation at the onset of acute and
persistent viral infections, identifying a continuous mechanism
limiting Th1 differentiation and preventing control of persistent
infection.
RESULTS
Combined PD-L1 and IL-10 Suppression Inhibits
De Novo CD4 Th1 Generation
To explore CD4 T cell dynamics and dysfunction in persistent
viral infection, we use the lymphocytic choriomeningitis virus
(LCMV) model. Infection with the LCMV variant clone 13 (Cl13)
establishes a persistent infection because of enhanced viral
replication and receptor affinity that outcompetes the developing
immune response, thereby inducing immunosuppression and
T cell exhaustion (Ahmed et al., 1984; Ng et al., 2013). To identify
the mechanisms that inhibit CD4 Th1 cell generation in the midst
of persistent infection, we isolated naive LCMV-specific CD4
TCR transgenic (SMARTA) cells and adoptively transferred
them into mice 1 hr prior to LCMV-Cl13 infection or 21 days
after LCMV-Cl3 infection (i.e., in an established persistent infec-
tion) (Osokine et al., 2014). Importantly, virus-specific CD4
SMARTA T cells mount analogous responses to their endoge-
nous polyclonal LCMV-specific I-Ab-restricted GP61–80 CD4Figure 1. Dual PD-L1 and IL-10 Expression Suppresses De Novo CD4
Mice infected for late-prime experiments were CD8-depleted prior to LCMV-Cl13
CD4 SMARTA T cells were transferred into mice 1 hr prior to LCMV-Cl13 infect
priming). One day prior to late priming, mice were treated with either isotype con
[DB]) blocking antibodies. Antibody treatment continued on days 1, 4, and 7 afte
(A) Flow plots depict the frequency and bar graphs the number of CD4 Th1 (SLA
SMARTA CD4 T cells.
(B) Flow plots and bar graphs depict the frequency of IFNg-, IFNg- and TNF-a-,
cells following ex vivo peptide stimulation. Also depicted in a bar graph is the geom
Data are representative of three to four independent experiments with three to s
See also Figure S1.
3288 Cell Reports 16, 3286–3296, September 20, 2016T cell counterparts. On day 8 post-transfer, the virus-specific
CD4SMARTA T cells primed at the onset of LCMV-Cl13 infection
(termed early-primed) differentiated into both Th1 cells (signaling
lymphocytic activation molecule [SLAM]hi CXCR5lo) and Tfh cells
(SLAMlo CXCR5hi), whereas virus-specific CD4 SMARTA T cells
primed in the midst of persistent viral infection (termed late-
primed) almost exclusively generated Tfh (Figure 1A; Osokine
et al., 2014). The suppression of late Th1 priming was overcome
by blocking type I interferon (IFN-I) signaling prior to priming (Fig-
ure 1A), but, interestingly, the effect was indirect on the T cells
(Osokine et al., 2014). IFNb is associated with the suppressive
qualities of the IFN-I system (Ng et al., 2015); however, similar
to untreated wild-type (WT) mice, no enhancement of Th1 prim-
ing was observed in IFNb/ mice (Figure S1A). Thus, our data
suggest that IFNb alone does not mediate the Th1-suppressive
capacity in the midst of persistent viral infection.
IFN-I drives IL-10 expression, and IL-10 is well recognized to
suppress Th1 differentiation (Cunningham et al., 2016; Moore
et al., 2001). To test the role of IL-10 in preventing new CD4
Th1 cell generation, an anti-IL-10R antibody was used. All mice
were depleted of CD8 T cells prior to infection to prevent the
decrease in virus titers by anti-IL-10R (Brooks et al., 2006; Ejr-
naes et al., 2006) or other blocking antibodies (Barber et al.,
2006) in persistent LCMV infection. Unexpectedly, IL-10R
blockade had a minimal restorative effect for late-primed CD4
Th1 cell differentiation compared with isotype antibody-treated
mice (Figure 1A). IFN-I signaling also directly induces PD-L1
expression during viral persistence (Cunningham et al., 2016),
and, although PD-L1 is not specifically identified to inhibit CD4
Th1 differentiation, its CD8 T cell-suppressive capacity is well es-
tablished (Barber et al., 2006). PD-L1 blockade alone induced a
moderate increase in CD4 Th1 cell priming during persistent
infection; however, the simultaneous blockade of both PD-L1
and IL-10R completely restored CD4 Th1 differentiation; in
fact, exceeding the recovery generated by blocking type I
interferon alpha receptor (IFNAR) (Figure 1A). The Th1 cells
that formed after the dual IL-10R and PD-L1 blockade produced
increased IFNg, tumor necrosis factor a (TNF-a) and granzyme
B (Figures 1A and 1B). Consistent with previous data, a
proportion of Tfh cells also produced IFNg after dual blockade
(Fahey et al., 2011) but at a substantially decreased percentage
of the population and dramatically lower per-cell levels than
Th1 cells (Figure 1B). Inhibition of late Th1 priming and its
restoration upon PD-L1 and IL-10R blockade were also
observed using CD4 TCR transgenic cells specific for the
LCMV-nucleoprotein311-325 (NIP TCR-transgenic mice) (Nance
et al., 2015; Figure S1B), indicating that the effect was a generalTh1 Generation during an Established Persistent Virus Infection
infection to prevent control of infection by blocking antibodies. Virus-specific
ion (early priming) or into mice infected 21 days earlier with LCMV-Cl13 (late
trol, anti-IFNAR, anti-IL-10R, anti-PD-L1, or anti-PD-L1 and IL-10R (dual block
r priming. Analysis was performed on the spleen on day 8 after priming.
Mhi CXCR5lo) and Tfh (SLAMlo CXCR5hi) cells or IFNg- and TNF-a-producing
and granzyme B-producing SLAM+ Th1 (red) and SLAM- Tfh (black) SMARTA
etric mean fluorescent intensity (GMFI) of IFNg on Th1 and Tfh SMARTA cells.
ix mice per group. Error bars depict SD. *p < 0.05.
Figure 2. IFN-I Induced PD-L1 and IL-10
Expression on Suppressive DCs Inhibits the
Priming of Th1 Cells
(A) Stimulatory DCs and suppressive DCs from
LCMV-Cl13-infected mice were co-cultured for
5 days with naive CD4 SMARTA T cells in the
presence of isotype or anti-PD-L1 + anti-IL-10R
blocking antibodies (DB). Flow plots show the fre-
quency and bar graphs the number of activated
Th1+-producing (CD62Llo T-bet+) and IFNg-pro-
ducing CD4 SMARTA T cells. No exogenous peptide
was added to the cultures for stimulation. Data are
shown from one of two experiments using DCs
pooled from 20 mice to obtain adequate numbers of
each population.
(B) Virus-specific CD4 SMARTA T cells were trans-
ferred into wild-type or CD11c-Cre IFNARfl/fl mice
infected 21 days earlier with LCMV-Cl13. Flow plots
depict the frequency and bar graphs the number of
CD4 Th1 and Tfh SMARTA cells in the spleen 8 days
after priming.
Data are representative of two independent experi-
ments with five mice per group. Error bars depict
SD. *p < 0.05.biological mechanism and not due to a specific TCR or a partic-
ular LCMV epitope.
IFN-I signaling upregulates PD-L1 expression by DCs (activa-
tion-inducible PD-L1) but does not control the basal level of PD-
L1 expression on DCs in the absence of inflammatory signals
(Wilson et al., 2013). Consistent with regulating activation-
induced expression, PD-L1 expression on DCs was decreased
by anti-IFNAR treatment, whereas it was completely blocked
by anti-PD-L1 (Figure S1C), suggesting that the remaining basal
levels of PD-L1 following anti-IFNAR blockade further diminish
Th1 priming. Changes in virus titers in CD8 T cell-depleted
mice are not responsible for the enhanced Th1 priming because
increased Th1 differentiation was observed in IL-10R/PD-L1
dually blocked mice where virus loads were slightly decreased
as well as in anti-IFNAR-treated mice where titers were
increased because of the loss of IFN-I antiviral activity (Fig-
ure S1D). Thus, IFN-I mediated induction of the suppressive
factors IL-10 and PD-L1 combinatorially suppresses de novo
CD4 Th1 priming and the production of polyfunctional cyto-
kine-producing CD4 T cells during an established persistent
virus infection.
DCs are required for priming CD4 T cells in the midst of persis-
tent LCMV infection (Osokine et al., 2014). We recently identified
two populations of DCs that emerge during persistent infection,
stimulatory (stim) DCs that robustly stimulate CD4 T cells and
suppressive (supp) DCs that are induced by IFN-I to express
multiple inhibitory molecules, including PD-L1 and IL-10 (Cun-
ningham et al., 2016). Of note, suppDCs have a similar
or elevated expression of major histocompatibility complex
(MHC) class I and II and of costimulatory molecules CD80 andCell ReportCD86 compared with stimDCs (Cunning-
ham et al., 2016; Wilson et al., 2012). To
determine how these different DC subsets
affect Th1 priming, we isolated suppDCsand stimDCs from LCMV-Cl13-infected mice and cultured
them with naive LCMV-specific CD4 T cells. SuppDCs sup-
pressed CD4 Th1 priming, generating a lower frequency and,
particularly, number of T-bet-expressing virus-specific CD4
T cells as well as fewer IFNg-producing cells than the stimDCs
(Figure 2A). PD-L1 and IL-10Rblockade reversed suppDC-medi-
ated inhibition and enabled robust CD4 Th1 activation and IFNg
production, even surpassing that observed when CD4 Th1 cells
were primed by stimDCs (Figure 2A), indicating that interaction
of naive CD4 T cells with IL-10/PD-L1-producing suppDCs
from persistent virus infection potently inhibits de novo CD4
Th1 cell priming. Additionally, virus-specific CD4 SMARTA
T cells primed in persistently infected CD11c-Cre IFNARfl/fl
mice exhibited increased Th1 generation compared with late
priming in WT mice (Figure 2B), confirming DCs as the target
of IFN-I suppression of de novo CD4 Th1 differentiation in vivo
in the midst of persistent viral infection.
IL-10 and PD-L1 Inhibit Th1 Differentiation at the Onset
of Acute and Persistent Virus Infection
IL-10 and PD-L1 are also expressed early in viral infection
(Barber et al., 2006; Brooks et al., 2010). To investigate their
role in suppressing CD4 Th1 differentiation at the onset of infec-
tion, PD-L1 and IL-10R were blocked prior to acute LCMV-
Armstrong (Arm) infection or persistent LCMV-Cl13 infection.
To avoid the mortality associated with anti-PD-L1 treatment at
the onset of LCMV-Cl13 infection (Barber et al., 2006), mice
were CD8-depleted prior to infection. Similar to its effects during
persistent infection, IL-10R plus PD-L1 blockade at the onset of
acute and persistent LCMV infection did not affect overall CD4s 16, 3286–3296, September 20, 2016 3289
Figure 3. PD-L1 and IL-10 Suppress Th1 Re-
sponses at the Onset of Acute and Persistent
Viral Infection
(A and B) Virus-specific CD4 SMARTA T cells were
transferred into mice 1 day prior to LCMV-Arm or
LCMV-Cl13 infection. LCMV-Cl13 infected mice
were CD8-depleted prior to infection. Mice were
treated with anti-PD-L1 and anti-IL-10R or isotype
control on days 0, 2, 5, and 8 after infection. Flow
plots depict the frequency and bar graphs the
number of (A) CD4 Th1 (SLAMhi CXCR5lo) and Tfh
(SLAMlo CXCR5hi) SMARTA cells and (B) IFNg and
TNF-a production and IFNg GMFI by splenic CD4
SMARTA T cells 9 days after infection. Data are
representative of two independent experimentswith
four mice per group. Error bars depict SD. *p < 0.05.
See also Figure S2.Tfh responses but dramatically increased the number of SLAM+/
Tbet+ virus-specific CD4 Th1 cells, almost entirely reorienting
the CD4 T cell response toward Th1 (Figures 3A and S2). PD-
L1 and IL-10R blockade increased the number of IFNg and of
dual IFNg/TNF-aproducing SMARTA cells in persistent LCMV
infection as well as the level of IFNg produced per cell in acute
and persistent infections (Figure 3B). Thus, IL-10 and PD-L1 sup-
press CD4 Th1 differentiation at the onset of acute and persistent
viral infection.
In Vitro Th1-Polarized Virus-Specific CD4 T Cells
Maintain Th1 Responses
Viral persistence converts CD4 Th1 cells to Tfh and inhibits new
Th1 cell generation (Fahey et al., 2011; Osokine et al., 2014).
Thus, whether generation of new Th1 cells can be maintained
to provide help for CD8 T cells in persistent infection is unclear.
To investigate the sustainability of CD4 Th1 cells during viral
persistence without the multiple direct and indirect effects
induced by PD-L1 and IL-10R blockade, virus-specific CD4
SMARTA T cells were Th1-polarized in vitro for 5 days and
then transferred into persistently infected mice 26 days after
infection. Further, mice were CD4-depleted prior to LCMV infec-
tion to generate a life-long viremic infection and enable long-
term analysis of CD4 Th1 cells in the continued presence of
high levels of virus replication (Matloubian et al., 1994). Depletion
of CD4 T cells prior to infection does not alter late-primed CD4
T cell differentiation or function (Osokine et al., 2014). In parallel,3290 Cell Reports 16, 3286–3296, September 20, 2016naive CD4 SMARTA T cells were trans-
ferred into a cohort of mice on day 21 after
LCMV-Cl13 infection for in vivo late prim-
ing to enable direct comparison with cells
primed at the same time that become Tfh
after priming in vivo (late-primed). The
number of Th1-polarized cells for transfer
was chosen to achieve roughly equal
amounts to the in vivo late-primed CD4
T cells on day 9 after priming, thus enabling
direct comparison (Figure 4A). Prior to
transfer, in vitro-polarized Th1 cells pro-
duced IFNg and TNF-a upon restimulation,expressed the Th1 transcription factor T-bet and high levels of
SLAM, and had little to no expression of CXCR5, confirming
Th1 polarization and demonstrating minimal contamination of
Tfh (Figure S3A). Four days after transfer into persistent infection
(9 days after priming), Th1-polarized virus-specific CD4 T cells
maintained cellular and molecular markers of Th1 differentiation,
including high expression of SLAM, T-bet, and P-selectin glyco-
protein 1 (PSGL1), which is downregulated in Tfh (Poholek et al.,
2010; Figures 4A and 4B; Figures S3B and S3C). Further, Th1-
polarized cells exhibited minimal expression of CXCR5 and the
Tfh transcription factor Bcl6 in contrast to the late-primed cells
that were predominantly Tfh (Figures 4A, 4B and S3C). PD-1
levels were lower in Th1-polarized cells compared with late-
primed CD4 T cells (Figures 4B and S3C), in accordance with
T-bet-mediated repression of PD-1 and increased PD-1 expres-
sion by Tfh (Haynes et al., 2007; Kao et al., 2011). However, upon
ex vivo restimulation, the amount of IFNg-producing, Th1-polar-
ized, virus-specific CD4 T cells was markedly decreased
compared with their pre-transfer levels (Figures 4C and S3A)
and was now similar to the production by late-primed virus-spe-
cific CD4 T cells (Figure 4C), suggestingmaintenance of CD4 Th1
cells but exhaustion of Th1 cytokine production upon entry into
persistent infection.
We next determined whether the CD4 Th1 cells could be sta-
bly maintained long-term in the presence of an ongoing persis-
tent infection. Although total numbers of in vivo late-primed
virus-specific CD4 T cells stayed relatively similar between
Figure 4. In Vitro Th1-Polarized Virus-Specific CD4 T Cells Sustain Long-Term Th1 Responses
Mice were CD4-depleted prior to LCMV-Cl13 infection to generate a life-long viral infection. Naive virus-specific CD4 SMARTA T cells were transferred 21 days
after LCMV-Cl13 infection (in vivo late prime [LP]) or primed in vitro under Th1-polarizing conditions for 5 days (Th1 Pol) and injected into mice on day 26 after
LCMV-Cl13 infection.
(A) Flow plots demonstrate the frequency and bar graphs the number of total, Th1 (SLAMhi CXCR5lo), and Tfh (SLAMlo CXCR5hi) CD4 SMARTA T cells in the late-
primed (black) and Th1-polarized (red) SMARTA populations in the spleen on days 9 and 40 after priming.
(B) Bar graphs show GMFI of T-bet, Bcl6, and PD-1 in the in vivo late-primed (black) or Th1-polarized (red) SMARTA CD4 T cells on day 9 after priming.
(C) Flow plots depict the frequency and bar graphs the number of IFNg-, TNF-a-, and IL-2-producing late-primed (black) or Th1-polarized (red) SMARTA CD4
T cells following ex vivo peptide stimulation of splenocytes on days 9 and 40 after priming.
Data are representative of three independent experiments with –three to five mice per group. Error bars depict SD. *p < 0.05. See also Figure S3.days 9 and 40 after priming, the total number of polarized CD4
T cells increased during this same time frame (Figure 4A). Of
the polarized cells initially transferred, the total number of Th1
cells remained the same between days 9 and 40 after priming
despite their decrease in proportion (Figure 4A). On day 40 after
transfer, the Th1 cells continued to express increased T-bet,
decreased PD-1, and lacked Bcl6 (Figures S3D and S3E), con-
firming the maintenance of Th1 differentiation. Despite initiallybeing a homogeneous Th1 population, a high frequency of
the Th1 polarized virus-specific CD4 T cells now expressed
CXCR5 and had downregulated SLAM (Figure 4A), indicating
the generation of a sustained, polyfunctional CD4 Th1 response
that could additionally give rise to Tfh cells during persistent virus
infection. Further, the initial functional exhaustion observed on
day 9 after transfer of the Th1-polarized cells was no longer
evident, and, on day 40, a large population of the polarizedCell Reports 16, 3286–3296, September 20, 2016 3291
Figure 5. Th1-Polarized Virus-Specific CD4 T Cells Enhance LCMV-Specific CD8 T Cells and Accelerate Viral Control
Virus-specific CD4 SMARTA T cells were primed in vitro under Th1-polarizing conditions for 5 days (Th1, red) and transferred into mice on day 27 after infection.
Additional cohorts of mice received naive virus-specific CD4 SMARTA T cells (LP, black) on day 22 after LCMV-Cl13 infection or no CD4 T cells (gray).
(A) Kinetics of LCMV Db/GP33–41 tetramer-positive CD8 T cell numbers in the blood.
(B) LCMVDb/GP33–41 tetramer-positive CD8 T cell numbers, PD-1 expression, and IFNg- and TNF-a-producing CD8 T cells following ex vivo peptide restimulation
with Gp33 peptide in the spleen on day 60 after infection.
(C) LCMV-specific and total plasma IgG.
(D) Plasma virus titers.
Data are representative of three independent experiments with five to nine mice per group. Error bars depict SD. *p < 0.05. See also Figure S4.CD4 Th1 cells expressed IFNg, TNF-a, and IL-2, and, in partic-
ular, there were increased amounts of double and triple cyto-
kine-producing cells (Figure 4C). Because of the initial CD4
depletion of mice prior to infection, virus titers remained high in
all mice (Figure S4A), indicating that the ability to sustain poly-
functional CD4 Th1 cells occurred despite the presence of
ongoing viral persistence.
Th1-Polarized Virus-Specific CD4 T Cells Enhance
LCMV-Specific CD8 T Cells and Accelerate Viral Control
CD8 T cells become progressively exhausted in persistent infec-
tion (Wherry et al., 2003), corresponding to the loss of CD4 Th1
cells (Fahey et al., 2011). We next determined how the loss of
CD4 Th1 cells as persistent infection progressed contributed
to the demise of antiviral immunity. CD4 Th1-polarized cells
were transferred into persistently infected mice at a time point
when the initial virus-specific CD4 Th1 cells are lost and primarily
only CD4 Tfh cells remain (day 27 after infection). In parallel, no
SMARTA cells or naive SMARTA cells were transferred on day
22 after persistent infection to generate Tfh cells. The number3292 Cell Reports 16, 3286–3296, September 20, 2016of naive SMARTA and Th1-polarized SMARTA were chosen so
that similar numbers of each were observed on day 9 after
priming, and a relatively small number of CD4 T cells were trans-
ferred compared with other studies (Aubert et al., 2011). Interest-
ingly, unlike the progressive decline in LCMV-specific CD8
T cells in persistently infected mice that received naive (late-
primed) SMARTA cells or that received no CD4 T cells, in mice
that received Th1-polarized cells, the total number of LCMV-
specific CD8 T cells in the blood was maintained throughout
persistent infection (Figure 5A). Further, mice that received
Th1-polarized CD4 T cells had increased numbers of LCMV-
specific CD8 T cells in the spleen 60 days after infection as
well as increased numbers of cytokine-producing CD8 T cells
and decreased PD-1 expression compared with those that
received no cells or late-primed Tfh (Figure 5B). Despite the
development of Tfh in the Th1-polarized transfer mice, neither
the addition of Th1-polarized nor in vivo-activated Tfh cells
significantly enhanced LCMV-specific immunoglobulin G (IgG)
or total IgG over levels generated by endogenous Tfh responses
(Figure 5C). Thus, maintaining CD4 Th1 cells sustained and
enhanced virus-specific CD8 T cell numbers and function but did
not affect virus-specific IgG levels.
The effects of sustaining CD4 Th1 help were not due to
changes in virus titers because Th1-polarized CD4 T cells simi-
larly enhanced virus-specific CD8 T cell numbers and function
when transferred into mice that had been CD4-depleted prior
to LCMV-Cl13 infection and that maintain life-long viremic infec-
tion (Figures S4A and S4B). In the CD4-depleted system, where
B cells had not received CD4 help at the onset of infection, the
transferred Th1-polarized CD4 T cells stimulated IgG production
similar to late-primed CD4 Tfh cells, consistent with gradual Tfh
accumulation in the Th1-polarized subset (Figure S4C). This is
distinctly different from the situation wherein initial CD4 help
had been provided but then Th1 cells waned whereas Tfh were
maintained, and no further help to antibody production was
evident (compare Figures 5C and S4C). Thus, CD4 Th1 transfer
enables help to CD8 T cells and B cells independent of changes
in viral titers when endogenous CD4 T cell help is absent.
The ability of Th1-polarized cells to sustain virus-specific CD8
T cell responses in the absence of enhanced antibody produc-
tion led us to question whether the reconstitution of CD4 Th1 im-
munity would enhance viral control. Viral titers were initially
similar between the groups at the time of cell transfer (Figure 5D).
However, by day 55 after infection, plasma virus titers were
below detection in mice that received CD4 Th1 cells, whereas
viremia remained elevated in mice that received no cells or
late-primed Tfh cells (Figure 5D). Thus, the loss of CD4 Th1 cells
impedes viral clearance, and their maintenance enhances anti-
viral immunity to accelerate control of an established persistent
virus infection.
DISCUSSION
Viral persistence severely restricts the breadth of CD4 T cell help,
favoring B cell help over Th1-mediated CD8 T cell help. However,
the mechanisms that inhibit CD4 Th1 differentiation, the stability
of Th1 cells if they could be generated, the overall effect of Th1
loss, and the disease consequences if these cells were reconsti-
tuted in persistent viral infection have remained unclear. Our
data demonstrate that PD-L1 and IL-10 expression by a specific
population of suppressive DCs inhibits de novo Th1 responses in
the midst of persistent viral infection. We demonstrate that the
loss of CD4 Th1 cells is a critical immune event driving progres-
sive CD8 T cell decline and dysfunction, thereby impeding con-
trol of persistent infection. Strikingly, therapeutically restoring
CD4 Th1 cells after they would have otherwise been lost stopped
the progressive decline in antiviral CD8 T cell responses, dimin-
ished CD8 T cell exhaustion, and enabled viral control. Thus, our
data indicate that the loss of CD4 Th1 cells is a critical factor
leading to progressive CD8 T cell demise during viral persistence
and undermining the ability to control persistent infection.
Prolonged CD4 Th1 responses are associated with enhanced
control of persistent virus infections, including HIV and HCV, and
the loss of Th1 cells correlates with decreased viral control (Ger-
lach et al., 1999; Rosenberg et al., 1997; Thimme et al., 2001).
However, it has been difficult to differentiate whether sustained
Th1 responses are the cause of virus control or a consequence
of the lower virus titers. Our data now answer this questionand demonstrate that the maintenance of CD4 Th1 cells pre-
vents the progressive decline in antiviral CD8 T cell numbers
and function to accelerate viral control. Unlike help to CD8
T cells when Th1 cells are lost, the ongoing Tfh cell response is
sufficient to sustain antibody production during viral persistence,
and no further enhancement in LCMV-specific IgG was afforded
by transfer of relatively small amounts of either Th1-polarized or
naive CD4 T cells that became Tfh cells upon priming. On the
other hand, in situations where B cells had never received CD4
T cell help, antibody production was enhanced by transfer of
Th1-polarized cells, indicating that, even after prolonged periods
of time in persistent infection, B cells retain the ability to produce
IgG if help is provided. Interestingly, the initial Th1-polarized cells
did not contain Tfh, indicating that the rise of CD4 Tfh cells was
derived from Th1 that became Tfh. This is similar to Th1 cells
primed at the onset of infection that convert into Tfh, but without
the loss of the initial Th1 cells that was observed in these studies
(Fahey et al., 2011), suggesting that established CD4 Th1 can
give rise to Tfh offspring while maintaining their initial identity.
Thus, the loss of CD4 Th1 cells as persistent infection pro-
gresses has an important effect on the decay of antiviral CD8
T cell responses, and, importantly, preventing this loss leads to
enhancedCD8T cell numbers and function and control of persis-
tent infection.
It is important to note that a balanced CD4 Th response con-
sisting of both Th1 and Tfh cells is likely optimal to control virus
infection. However, in the situation of viral persistence, this bal-
ance is disrupted and skewed toward Tfh. Our data now indicate
that restoring the Th1 side of the Th1/Tfh balance can comple-
ment the already ongoing B cell help promoted by the accumu-
lating Tfh response to simultaneously prevent the decay and
sustain the antiviral CD8 T cell responses required to optimally
fight persistent viral infection.
There is considerable interest in understanding the mecha-
nisms through which immune checkpoint inhibition restores im-
mune function to control disease. PD-L1 blockade has been
shown to augment antigen-specific CD4 T cell responses
(Aubert et al., 2011; Barber et al., 2011; Day et al., 2006); how-
ever, a specific modulation of Th subsets by PD-L1 as opposed
to a general suppression of all CD4 T cells has not been demon-
strated. Our data now add a mechanism of suppression by PD-
L1 during persistent viral infection: the prevention of new CD4
Th1 cells into the antiviral repertoire. Functionally, almost all of
the restored CD4 Th1 cells from the dual blockade produced
IFNg in conjunction with additional cytokines/antiviral effector
molecules, and these functional Th1 cells produced significantly
more of these molecules on a per-cell basis. Surprisingly, the
effect of PD-L1 and IL-10 was specific to CD4 Th1 cells and
had little effect on Tfh cells, demonstrating a bifurcation in the
factors and priming cell types that lead to Th1 versus Tfh fate de-
cisions. In contrast to themidst of persistent infection, where Th1
cell priming is significantly impaired, Th1 cells do form at the
onset of infection, but the generation of CD4 Th1 cells can still
be further enhanced by blocking IL-10 and PD-L1 signaling.
Thus, at the onset of infection, PD-L1 and IL-10 most likely serve
to dampen Th1 differentiation and diversify the CD4 helper
response because exacerbated Th1 responses are associated
with pathology and lethality (Barber et al., 2011; GazzinelliCell Reports 16, 3286–3296, September 20, 2016 3293
et al., 1996; Sun et al., 2009). Thus, we now establish an addi-
tional mechanism of PD-L1-induced immunosuppression during
viral persistence and demonstrate that the joint action of PD-L1
and IL-10 serves as a continuous CD4 Th1-suppressing mecha-
nism throughout persistent infection.
PD-L1 and IL-10 signaling are important suppressive factors in
many persistent viral infections, including HIV, SIV, and HCV,
which also show gradual erosion of CD4 Th1 cells, accumulation
of Tfh, and progressively diminished CD8 T cell responses (Feng
et al., 2012; Lindqvist et al., 2012; Petrovas et al., 2012). Our data
nowsuggest that thedecline in antiviral CD8Tcells in these infec-
tionsmay also in part be due to an inability tomaintain and invoke
newCD4Th1cells. Consistentwith themechanismweobserve in
persistent LCMV infection, denovo induction ofHIV-specificCD4
Th1 cells only occurred in patients with suppressed virus loads
(Lichterfeld et al., 2004), suggesting that active viral replication
also limits the induction of de novo Th1 responses in multiple
persistent infections. Thus, the ability to block PD-L1 and IL-10
and restore Th1 priming may be therapeutically beneficial to
generate the CD4 Th1 help needed to sustain and enhance anti-
viral CD8 T cell responses. Although PD-L1 therapy is most often
recognized for its direct effects on antiviral CD8 T cells, it likely
functions through multiple mechanisms (Nguyen and Ohashi,
2015), and our data suggest that an additional aspect of PD-L1
blockade therapy may be to enhance ctyolytic T lymphocyte
(CTL) responses indirectly by allowing for the generation of new
CD4 Th1 cells and the cytokines they produce.
With the success of adoptive immunotherapy to fight persis-
tent virus infection and cancer, the ability to reconstitute and
re-establish a patient’s T cells to fight disease is becoming a re-
ality. Our results have important implications for CD4 T cell
immunotherapy and demonstrate that therapeutic reconstitution
of CD4 Th1 cells can accelerate control of persistent infection.
Thus, de novo induction and/or adoptive transfer of antigen-spe-
cific CD4 Th1 cells might provide enhanced and prolonged help
to sustain CTL responses and facilitate viral control. Similarly,
this approach has been hypothesized for cancer immunotherapy
(Dobrzanski, 2013). Indeed, in various cancer models, polarized
CD4 Th1 cells and the cytokines they produce can mediate tu-
mor rejection, typically in a CD8 T cell-dependent manner (Moel-
ler et al., 2007; Nishimura et al., 1999), indicating that the ability
to maintain strong Th1 effector functions over time in the tumor
setting may also be pivotal for prolonged CD8 T cell help.
Because CD4 T cells are central to sustain the diverse facets
of the immune response in situations of chronic antigen stimula-
tion, future immunotherapeutic strategies should consider the
reconstitution of CD4 Th1 cells in their regiments but should be
mindful of how the antigenic environment can prevent new and
skew established CD4 Th1 cell responses.
EXPERIMENTAL PROCEDURES
Mice and Virus Infection
C57BL/6 mice were purchased from Jackson Laboratories the rodent
breeding colony at the University of California, Los Angeles (UCLA), or the Prin-
cess Margaret Cancer Center. LCMV-GP61–80-specific transgenic (SMARTA)
mice have been characterized previously and were bred on a Ly5.1 back-
ground. LCMV-NP311-25-specific transgenic (NIP) mice (Nance et al., 2015)
and IFNb/micewere generously provided byDr. ShaneCrotty (La Jolla Insti-3294 Cell Reports 16, 3286–3296, September 20, 2016tute for Allergy and Immunology) and Dr. Eleanor Fish (University of Toronto),
respectively. CD11c-Cre IFNARfl/fl mice were generated by crossing CD11c-
Cre mice (Jackson Laboratories) with IFNARfl/fl mice (Detje et al., 2009) gener-
ously provided by Dr. Ulrich Kalinke (Hannover Medical School). All mice
were housed under specific pathogen-free conditions. Animal studies were
approved by the UCLA Chancelor’s Animal Research Committee (ARC) or
the Ontario Cancer Institute (OCI) Animal Care Committee at the PrincessMar-
garet Cancer Center/University Health Network. Mice were infected intrave-
nously in the retro-orbital sinus with 2 3 106 plaque-forming units (PFUs) of
LCMV-Armstrong or clone 13. Viral stocks were prepared and titered as
described previously (Brooks et al., 2005).
In Vivo Cell Depletion and Blocking Antibody Treatments
Mice were administered 125 mg of anti-CD4 (GK1.5) or anti-CD8a (2.43) anti-
body both 4 days prior to and 1 day prior to infection. CD4 or CD8 depletion
was confirmed with flow cytometry using a non-blocking CD4 clone (RM4.4)
or an antibody to CD8b. For in vivo blocking experiments, either 500 mg anti-
IFNAR (MAR1), 250 mg anti-PD-L1 (10F.9G2), 250 mg anti-IL-10R (1B1.3A),
250 mg anti-PD-L1 plus 250 mg IL-10R, or appropriate isotype controls
(HPRN, LTF-2, or mouse IgG1) were administered 1 day prior to CD4 T cell
transfer and then on day 1 after priming and every 3 days thereafter for two
treatments. Anti-IFNAR dose was decreased to 250 mg for the last two injec-
tions. In blocking experiments during acute and persistent LCMV infection,
mice were administered 250 mg of anti-PD-L1 and anti-IL-10R or isotype con-
trols on days 0, 2, 5, and 8 of infection. In vivo blocking and depletion anti-
bodies were obtained from Bio X Cell, except anti-IFNAR, which was obtained
from Leinco Technologies.
Isolation and Polarization of Virus-Specific CD4 T Cells
CD4 T cells were isolated from the spleens of naive SMARTA or NIP transgenic
mice using a negative selection mouse CD4 T cell enrichment kit (Stem Cell
Technologies). For in vivo priming, 5,000 naive SMARTA or NIP transgenic
cells were injected i.v. via the retro-orbital sinus on day 21 or day 22 after
LCMV-Cl13 infection. For in vitro polarization, naive SMARTA cells were acti-
vated with plate-bound anti-CD3 (10 mg/ml) and soluble anti-CD28 (1 mg/ml).
Cells were further cultured with IL-12 (10 ng/ml) and anti-IL-4 (10 mg/ml) for
Th1 polarization. Antibodies were purchased from Bio X Cell and cytokines
from PeproTech. T cells were polarized for 5 days with a medium and cytokine
change on day 3 of culture. Five days after in vitro activation, 500,000 Th1-
polarized SMARTA cells were transferred into day 26 or day 27 LCMV-Cl13-
infected mice. This time point was chosen to temporally match time after
priming with the late-primed cells. Transfer of this amount of in vitro Th1-polar-
ized cells was chosen to attain equal numbers of in vivo late-primed and
in vitro-primed SMARTA on day 9 after priming. For in vivo priming at the onset
of LCMV-Arm or LCMV-Cl13 infection, 1,000 and 5,000 SMARTA cells,
respectively, were transferred 1 day prior to LCMV infection.
Tissue Isolation, Intracellular Cytokine Restimulation, and Flow
Cytometry
Single cell suspensions were prepared from all organs. Cells isolated from
organs were stained ex vivo using antibodies to CD4 (GK1.5), CD8 (53-6.7),
CD45.1 (A20), SLAM (TC15-12F12.2), CXCR5, (2G8), PSGL1 (2PH1), Ly6C
(HK1.4), PD-1 (29F.1A12), PD-L1 (10F.9G2), and IL-10R (1B1.3A). Dendritic
cells were identified by staining for CD45 (30-F11), CD11c (N418), CD11b
(M1/70), CD95 (15A7), CD39 (24DNS1), CD90.2 (30-H12), NK1.1 (PK136),
and Ly6G (1A8). All antibodies were from BioLegend with the exception of
CXCR5 (BD Biosciences). Staining for T-bet (4B10, BioLegend), Bcl6 (K112-
91, BD Biosciences), and Granzyme B (GB11, BioLegend) was performed as
directed using the Foxp3 staining kit (eBioscience). The H-2Db Gp33 tetramer
was obtained from the NIH Tetramer Core. Samples were run on a FACS Verse
(BD Biosciences), and data were analyzed using Flow Jo software (Tree Star).
For cytokine quantification, splenocytes were restimulated for 5 hr at 37C
with 5 mg/ml of MHC class II-restricted LCMV peptide GP61–80 in the presence
of 50 U/ml recombinant murine IL-2 and 1 mg/ml brefeldin A (Sigma). Pre-
transfer polarized T cells were restimulated with 50 ng/mL phorbol-myris-
tate-acetate (PMA) + 1 mM ionomycin for 5 hr to assess cytokine production.
Following the 5-hr in vitro restimulation, cells were stained with a fixable
viability stain, Zombie Aqua (BioLegend), extracellularly stained as above with
CD4 and CD45.1, and fixed, permeabilized, and stained with IFNg (XMG1.2),
TNF-a (MP6-XT22), and IL-2 (JES6-5H4) (BioLegend).
APC Subset Sorting and In Vitro T Cell Stimulation
Sorting of suppressive and stimulatory DCs was carried out as described pre-
viously (Cunningham et al., 2016). Briefly, mouse splenocytes were pooled and
enriched for CD11c-positive cells using CD11c MicroBeads (Miltenyi Biotec)
and an autoMACS (Miltenyi). Enriched cells were extracellularly stained for
suppressive DCs (CD45+, CD11c hi, CD11b+, CD95hi, CD39hi, CD90.2,
NK1.1, and Ly6G) and stimulatory DCs (CD45+, CD11c hi, CD11b+,
CD95lo, CD39lo, CD90.2, NK1.1, and Ly6G) and sorted by fluores-
cence-activated cell sorting (FACS) on a Moflo Astrios (Beckman Coulter).
The post-sorting purity was >95%. Antigen-specific CD4+ T cells (SMARTA)
were isolated from the spleens of naive mice as above and cultured for
5 days with sorted immunoregulatory dendritic cells (iregDCs) or stimDCs at
a ratio of 2:1 T cells to dendritic cell populations (80,000 T cells to 40,000
DCs). Antibodies against PD-L1 (1F.9G2) and IL-10R (1B1.3A) or appropriate
isotype controls (HPRN and LTF-2) were added at a concentration of
10 mg/ml to the appropriate wells. For IFNg quantification, the cultures were
stimulated with 50 ng/ml PMA + 1 mM ionomycin in the presence of 1 mg/ml
brefeldin A (Sigma) for the last 5 hr of incubation.
Antibody ELISA
Plasma total IgG or LCMV-specific IgG ELISAs were performed using Maxi-
sorp ELISA plates (Nunc) coated overnight with goat anti-mouse IgG (Southern
Biotech) or 5 3 106 PFUs/well of LCMV-Cl13. Plates were blocked with BSA/
PBS/0.05% Tween 20. Serial dilutions of mouse plasmawere incubated on the
plates, washed, and incubated with horseradish peroxidase (HRP)-labeled
goat anti-mouse IgG (Life Technologies), followed by addition of the substrate
o-phenylenediamine in 0.05 M phosphate buffer. The reaction was stopped
with 2 N H2SO4, and the optical density (OD) values were read at 490 nm. Anti-
body concentrations were quantified by interpolating plasma dilutions falling
within a standard curve (500–0.245 ng) generated from serial dilutions of puri-
fied mouse IgG (Aviva Systems Biology Corp.).
Statistical Analysis
Student’s t tests (two-tailed, unpaired) and Mann-Whitney nonparametric
tests (two-tailed, unpaired) were performed using GraphPad Prism software.
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